Investigating the mechanisms of small molecule separation in blood plasma

肾脏的主要功能之一是将尿毒症毒素从血液中分离出来。目前，透析是从血液中分离尿毒症毒素的主要技术。在这方面，终末期肾病(ESRD)是一个全球健康问题，患病率很高(15%-全球；30%-加拿大)。终末期肾病患者的主要治疗方法是血液透析，血液通过半透膜，尿毒症毒素扩散到透析液中。这是一个重复、费力、耗时且昂贵的过程。位于安大略省基奇纳的Qidni Labs Inc.正在开发肾脏替代疗法，该疗法将消除透析诊所会议的必要性，并将实施持续和自动的肾脏疗法。在这项提案中，QidniLabs Inc.和Praveen Nekkar Rao博士(滑铁卢大学药学院副教授)合作，研究使用新型微流控平台分离尿毒症毒素的替代方法，并使用分析工具进行检测。这项建议旨在研究使用新型微流控平台分离尿毒症毒素的新方法，并使用分析工具进行检测。这些结果有望揭示使用微流控技术进行小分子分离的机制及其在加拿大肾脏患者中的潜在应用，从而为加拿大人提供健康和经济利益。

One of the key functions of kidneys is to separate uremic toxins from the blood. Currently, dialysis is the maintechnique of separation of uremic toxins from blood. In this regard, End Stage Renal Disease (ESRD) is aglobal health concern with a high prevalence percentage (15% - global; 30% - Canada). The leading treatmentfor ESRD patients is hemodialysis, where the blood is passed through a semipermeable membrane and theuremic toxins diffuse into the dialysate. This is a repetitive, laborious, time consuming and expensive process.Qidni Labs Inc., Kitchener, Ontario is developing renal replacement therapies that will eliminate the necessityof dialysis clinic sessions and will administer continuous and automatic renal therapy. In this proposal QidniLabs Inc. and Dr. Praveen Nekkar Rao (Associate Professor, School of Pharmacy, University of Waterloo) arecollaborating to investigate alternative methods of separating uremic toxins using a novel microfluidic platformand their detection using analytical tools. This proposal aims to investigate novel methods of separating uremictoxins using a novel microfluidic platform and their detection using analytical tools. The outcomes areanticipated to reveal the mechanisms of small molecule separation using the microfluidic technology and theirpotential application to kidney patients in Canada thereby providing health and economic benefits toCanadians.